WGS
Get informed when a big investor buys or sells
+ FollowOvervalued by 277.2% based on the discounted cash flow analysis.
| Market cap | $2.33 Billion |
|---|---|
| Enterprise Value | $2.44 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.73 |
| Beta | 1.98 |
| Outstanding Shares | 29,710,139 |
| P/E Ratio | -21.45 |
|---|---|
| PEG | 8.12 |
| Price to Sales | 5.28 |
| Price to Book Ratio | 9.89 |
| Enterprise Value to Revenue | 5.36 |
| Enterprise Value to EBIT | -36.16 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.69 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0566▼ 41.47% |
|---|---|
| Total Calls | 15,900▼ 96.17% |
| Total Puts | 900▼ 99.54% |
Holdings and activity of institutional investors.
| Ownership % | 18.01%▼ 88.52% |
|---|---|
| Total Invested | $362.70M▼ 81.94% |
| Investors Holding | 86▼ 167.00% |
No data
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and g...